I don't think INSY is pure a cannabis play. They are more diversify than GW.
In any event, the last thing I want to see is GW utilizing all these funds to finance clinical trials for Sativex and Epidiolex and NOT get FDA approval for them. And worse, that means GW would have to issue more shares to finance the next drug in the pipeline.
Constantly issuing more shares is not a viable business model especially for shareholders. That is why we need FDA approvals and get the drugs out to start generating profits.
The first FDA approval is the hardest to get.